If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

SAN FRANCISCO, February 13, 2025 -- ( BUSINESS WIRE )-- Junevity, a biotechnology company on a mission to extend lifespan and ...

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock. The post Up 135% in a year ...

A new article, published in the International Journal of Environmental Research and Public Health, unveils a software application that transforms patients' homes into therapeutic environments for ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapi ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

According to the results of a new study, a cannabidiol (CBD) hydrogel microneedle patch may offer significant therapeutic ...